Myriad Genetics, Inc. (MYGN:NASDAQ) closed at $4.09 on October 14, 2026, up 0.25% on the day. The stock trades 52.4% below its 52-week high of $8.59 and 49.3% above its 52-week low of $2.74. Over the past year, it lost 47.7%. Myriad Genetics, Inc. is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.34% | +7.65% | -34.09% | -19.69% | -47.69% |
In 252 trading sessions since October 13, 2025, MYGN closed higher on 120 days (48%). Its best day was June 24, 2026 (+12.74%) and its worst was July 31, 2026 (-46.74%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease; identify a patient's likelihood of responding to drug therapy; guide a patient's dosing to ensure optimal treatment; and assess a patient's risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and pol...
Find more stocks like MYGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.